A large-scale study of older adults in U.S. nursing facilities has found a potential link between the Shingrix shingles vaccine and a 24% reduced risk of dementia over a four-year period. The research, published in Nature Medicine, analyzed data from 509,926 adults aged 66 and older across more than 5,500 skilled nursing facilities between 2017 and 2022. Among those who received the Shingrix vaccine, 18.8% developed dementia, compared to 24.6% of unvaccinated individuals, suggesting that one dementia case could be prevented for every 17 people vaccinated. The findings add to growing evidence that the vaccine may offer broader health benefits beyond its intended use.
Study Details and Methodology
The research, led by Dr. Maxime Taquet of the University of Oxford, examined Medicare claims data and electronic health records to compare dementia rates between vaccinated and unvaccinated participants. The study employed target trial emulation, a method designed to approximate randomized clinical trials using observational data. Participants were eligible for shingles vaccination and had no prior dementia diagnosis. The Shingrix vaccine, introduced in 2017, is the only shingles vaccine currently available in the U.S. and replaced the older Zostavax vaccine in 2023 due to safety concerns for immunocompromised individuals.
Potential Additional Health Benefits
Beyond dementia risk reduction, the study suggests the Shingrix vaccine may also lower the risk of cardiovascular events, including heart disease, stroke, and heart failure. Researchers found a 12% reduction in major cardiovascular events among vaccinated individuals compared to those who received the older Zostavax vaccine. The study analyzed data from over 70,000 adults aged 60 and older in the U.S., matching participants for factors such as age, sex, ethnicity, and pre-existing health conditions. Dr. Taquet noted that if confirmed in clinical trials, the Shingrix vaccine could represent the first vaccine to protect both heart and brain health.
Implications for Public Health Policy
The findings have prompted calls for increased vaccination uptake, particularly among older adults. In the UK, the Shingrix vaccine is currently offered to adults aged 65–79 through the NHS, with eligibility expanding to include immunocompromised individuals. Researchers estimate that tens of thousands of deaths could be prevented in the UK alone if all eligible individuals received the vaccine. The study’s authors emphasize that while the results are promising, further clinical trials are needed to confirm the vaccine’s protective effects against dementia and cardiovascular disease.
Expert Reactions and Cautious Optimism
Experts not involved in the study have described the findings as encouraging but preliminary. Dr. Kaley Hayes, lead author of a related study published in Nature Medicine, noted that the research aligns with earlier studies examining the older shingles vaccine, which also suggested a potential link to reduced dementia risk. However, she cautioned that observational studies cannot establish causation, and randomized controlled trials are necessary to validate the results. The study’s authors acknowledge these limitations, stating that the observed associations may be influenced by unmeasured factors, such as lifestyle or socioeconomic status.
Next Steps for Research and Public Health
The study’s authors are calling for further research to explore the biological mechanisms underlying the potential protective effects of the Shingrix vaccine. One hypothesis suggests that the vaccine may reduce chronic inflammation, a known contributor to both dementia and cardiovascular disease. Additionally, researchers are investigating whether the vaccine’s impact on the immune system could play a role in brain health. Public health officials are urged to consider these findings when updating vaccination guidelines, particularly for high-risk populations.
Key Takeaways for Older Adults
- The Shingrix vaccine may reduce the risk of dementia by 24% over four years.
- The vaccine is currently recommended for adults aged 65 and older in the U.S. and UK.
- Potential additional benefits include a 12% reduction in cardiovascular events.
- Further research is needed to confirm these findings and understand the underlying mechanisms.